Astellas boosts ocular pipeline with gene therapy acquisition
15-08-2018
Astellas accuses Cipla of infringing overactive bladder patent
07-06-2018
designer491 / iStockphoto.com
UK-based Crescendo Biologics has agreed a global licensing deal with biopharma company Zai Lab which will see Zai Lab develop and commercialise an antibody, “VH domain therapeutic”, for applications in inflammatory diseases.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Crescendo Biologics, Zai Lab, Takeda, Astellas, collaboration, licensing agreement, psoriasis, biologics
